This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baqar, S.
Right arrow Articles by Guerry, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baqar, S.
Right arrow Articles by Guerry, P.

 Previous Article  |  Next Article 

Infection and Immunity, July 2008, p. 3170-3175, Vol. 76, No. 7
0019-9567/08/$08.00+0     doi:10.1128/IAI.00076-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Immunogenicity and Protective Efficacy of Recombinant Campylobacter jejuni Flagellum-Secreted Proteins in Mice{triangledown}

Shahida Baqar,* Lisa A. Applebee, Theron C. Gilliland Jr., Lanfong H. Lee, Chad K. Porter, and Patricia Guerry

Enteric Diseases Department, Naval Medical Research Center, Silver Spring, Maryland

Received 18 January 2008/ Returned for modification 4 March 2008/ Accepted 10 April 2008

Immunogenicity and protective efficacy of three Campylobacter jejuni flagellum-secreted proteins, FlaC, FspA1, and FspA2, were compared by use of a mouse model. Mice were immunized intranasally with each protein with or without LTR192G as the adjuvant and challenged intranasally with C. jejuni 81-176 or CG8486. All three proteins were immunogenic, although FspA1 induced the highest levels of serum immunoglobulin G (IgG) and fecal IgA. Although immunogenic, FlaC provided only 18% protection against disease from C. jejuni 81-176. Immunization with FspA1 resulted in 57.8% protection without adjuvant or 63.8% protection with adjuvant against homologous challenge with 81-176. Alternatively, immunization with FspA2 provided 38.4% (without adjuvant) or 47.2% (with adjuvant) protection against disease from homologous challenge with CG8486. In contrast to FspA2, FspA1 provided some heterologous protection against C. jejuni CG8486 when delivered with (31.2%) or without (44.8%) LTR192G. These results suggest that FspA1 may be a good subunit vaccine candidate against C. jejuni disease.

* Corresponding author. Mailing address: Enteric Diseases Department, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500. Phone: (301) 319-7672. Fax: (301) 319-7679. E-mail: shahida.baqar{at}med.navy.mil

{triangledown} Published ahead of print on 21 April 2008.

Editor: J. B. Bliska

Infection and Immunity, July 2008, p. 3170-3175, Vol. 76, No. 7
0019-9567/08/$08.00+0     doi:10.1128/IAI.00076-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»